Aravindhan Veerapandiyan
Associate Professor
Also affiliated: Rutgers, The State University of New Jersey (2013–2018); University of Iowa (2019); Arkansas Children's Hospital (2018–2026); Children's National (2024); University of Louisville (2020); University of Miami (2020); Duke University (2011); SUNY Downstate Health Sciences University (2018); University of Arkansas Medical Center (2022–2026); University of Rochester Medicine (2018–2020); Stony Brook School (2018); Stony Brook Medicine (2018); University of Applied Management Studies (2022–2023); Duke Medical Center (2010–2015); Duke University Hospital (2011–2013); PSG Institute of Advanced Studies (2014); Rutgers New Jersey Medical School (2016–2017)
Faculty Researcher
Peds Pediatrics, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Aravindhan Veerapandiyan's research focuses on the genetic and therapeutic interventions for neuromuscular and neurological disorders, with a particular emphasis on Duchenne muscular dystrophy and spinal muscular atrophy. He has been involved in clinical trials for novel gene therapies, including the EMBARK phase 3 randomized trial for AAV gene therapy in Duchenne muscular dystrophy and an expanded access program for risdiplam in spinal muscular atrophy. His work also extends to understanding the molecular underpinnings of conditions like autism spectrum disorder and X-linked intellectual disability syndromes.
Veerapandiyan has also investigated the implementation of pharmacogenomics testing in a clinical setting and explored the incidence of PANDAS and PANS in primary care populations. His scholarship metrics include an h-index of 20, with 133 total publications and 1,416 citations. He leads a research group at the University of Arkansas for Medical Sciences and collaborates with several colleagues within the institution, including Akilandeswari Aravindhan, Praveen Kumar Ramani, Ruthwik Duvuru, and Murat Gökden.
Metrics
- h-index: 20
- Publications: 134
- Citations: 1,447
Selected Publications
-
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial (2026)
-
Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions (2026)
-
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up (2026)
-
Caregiver perception of cardiac disease and advanced cardiac therapies in Duchenne muscular dystrophy: A national survey (2026)
-
Pathologic Variability Associated With Phenotypic Differences in Siblings With <scp>ACTA1</scp> Myopathy (2026)
-
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study (2026)
-
Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management (2026)
-
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial (2026)
-
Assessing Delays in Time to Diagnosis of Duchenne Muscular Dystrophy: A Survey of Current Primary Care Practices (2025)
-
Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone (2025)
-
Caregiver Perception of Cardiac Disease and Advanced Cardiac Therapies in Duchenne Muscular Dystrophy: A National Survey (2025)
-
Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial (2025)
-
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy (2025)
-
Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy (2024)
-
Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Clinical Neurobehavioral Screening Tool for Duchenne and Becker Muscular Dystrophy UAMS ACHRI Flow Through Principal Investigator
Collaboration Network
Top Collaborators
- Congenital Myasthenic Syndrome due to a Novel Mutation in CHAT Gene
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- Exercise Intolerance and Rhabdomyolysis Due to Dystrophinopathy: A Pseudometabolic Presentation
- Infantile-Onset Complex Hereditary Spastic Paraplegia Due to a Novel Mutation in SPAST Gene
- A rare neuro-ophthalmological phenomenon: Marcus Gunn jaw winking ptosis
Showing 5 of 6 shared publications
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Palliative care in Duchenne muscular dystrophy: Goals of care discussions and beyond
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Mitochondrial Ultrastructural Defects in NDUFS3-Related Disorder
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- Miyoshi Muscular Dystrophy Due to Novel Splice Site Variants in <i>DYSF</i> Gene
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy
- Congenital Myasthenic Syndrome due to a Novel Mutation in CHAT Gene
- A rare neuro-ophthalmological phenomenon: Marcus Gunn jaw winking ptosis
- A rare neuro-ophthalmological phenomenon: Marcus Gunn jaw winking ptosis
- Industry Payments to Pediatric Neurologists: An Analysis from the Open Payments Program
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- Miyoshi Muscular Dystrophy Due to Novel Splice Site Variants in <i>DYSF</i> Gene
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies
- Charcot‐Marie‐Tooth disease in children
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy
Similar Researchers
Based on overlapping research topics